drugset / Trial / NCT04297436

Gonococcal Vaccine Study in Key Populations in Kenya

NCT04297436

NaSingle-groupOpen-labelBasic science

Summary

Gonorrhoea is a sexually transmitted infection that can infect both men and women. It can cause infections in the genitals, rectum, and throat. It is a very common infection, especially among young people aged 18-25 years. Meningococcal disease and gonorrhoea are caused by bacteria that are closely related but cause different diseases that are spread in different ways. New evidence suggests that the Meningococcal B vaccine (Bexsero®) licensed outside of Kenya against meningococcal B disease may also be effective against gonorrhoea due to genetic similarities between the two organisms causing the two diseases. The aim of this study is to generate data to develop a gonorrhoea vaccine, using an existing vaccine against meningococcal disease

Timeline

Start
2021-05-31
Primary completion
2022-02-05
Completion
2022-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexsero Vaccine

Indications